This is a snippet of the transcript, sign up to read more.
Usually, if a part costs $100, the PMA would most likely sell for around $60. A repair would sell for $30 or $40. The price of used serviceable parts was always unpredictable. Depending on the market availability, sometimes you could get used serviceable or used parts for pennies or dimes on the dollar. However, the key was to be more aware of the competitive intensity at a part level basis. You might reduce the price on the piece part, but then you would compensate for it by increasing the prices on the non-PMA parts within the next higher assembly or component. This way, you'd end up with the same or better profit.
This is a snippet of the transcript, sign up to read more.
The third strategy would be to use your leverage, not necessarily with a large company like Delta, but with smaller, lesser airlines and MROs. You would make them sign agreements that essentially banned them from using PMAs. You would also reserve audit rights so you could conduct an inventory review. If they had PMAs in their inventory, you had strong clauses in your contract to take action against them. This was the strategy that Honeywell and GE adopted. There are other nuances to it, but those are the main points.
This is a snippet of the transcript, sign up to read more.
Honeywell was unlikely to allow Wencor or Heico to become a distributor for them due to various reasons. However, we did have some PMAs on their products. The relationship was essentially a mathematical equation. If we, as a distributor, could make more profit by getting, let's say, 12% 14% margin on selling $50 million, as opposed to getting 60% to 70% on the two million PMAs that I was selling, it was just a matter of calculation.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research